ARWR Stock On Track To Hit Over 5-Year Highs – Retail Cheers Phase 3 Breakthrough As Arrowhead Targets Broader FDA Approval

Arrowhead Pharmaceuticals reported positive topline results from two Phase 3 studies for its hypertriglyceridemia therapy.

ARWR stock is on track to hit over 5-year highs following the Phase 3 breakthrough.

Retail investors are cheering the news as Arrowhead targets broader FDA approval.